{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045275","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.132079+00:00","generated_at":"2026-06-07T11:21:34.845154+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"confidence":"high","headline":"AgeX shareholders approve Juvenescence proposal allowing increased stake via preferred conversion","bullets":["Juvenescence proposal approved: 18,908,391 for, 7,461,795 against, 38,095 abstain; 4.8M broker non-votes.","Three directors re-elected: Bailey (18.6M for), Hackett (18.9M), Renondin (19.7M); broker non-votes 4.8M each.","Auditor WithumSmith+Brown ratified: 23.5M for, 7.3M against, 496,875 abstain.","Meeting held Dec 13, 2023; 82.36% of 37.95M shares represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045275","json":"https://secwatch.observer/filing/0001493152-23-045275.json","markdown":"https://secwatch.observer/filing/0001493152-23-045275.md","text":"https://secwatch.observer/filing/0001493152-23-045275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:21:34.845154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0eb87bfa6e19bb9870d23d50b82d78707abe97bd","claim":"Serina Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accountants at the 2023-12-13 meeting.","evidence_excerpt":"The appointment of WithumSmith + Brown PC as our independent registered public accountants for the fiscal year ending December 31, 2023 was ratified by the following vote: Shares Voted For 23,460,256 Against 7,298,688 Abstain 496,875","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-13"}],"fact_type":"shareholder_vote"},{"claim_id":"5bd8aef1a4a2e9365c0930d19ffe4a8f53dae788","claim":"Serina Therapeutics, Inc. shareholders approved Proposal to permit Juvenescence Limited to acquire additional shares through conversion of Series B Preferred Stock at the 2023-12-13 meeting.","evidence_excerpt":"The Juvenescence was approved by the following vote: Shares Voted For 18,908,391 Against 7,461,795 Abstain 38,095","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-13"}],"fact_type":"shareholder_vote"},{"claim_id":"f4a6eaa2ceaee7f32f14b68277c658aede8e851c","claim":"Serina Therapeutics, Inc. shareholders approved Election of three directors at the 2023-12-13 meeting.","evidence_excerpt":"Each of the following nominees were elected as directors by the following vote: Nominee Votes For Votes Withheld Gregory Bailey 18,629,281 7,779,000 Joanne Hackett 18,946,164 7,462,117 Jean-Christophe Renondin 19,707,041 6,701,172","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}